JP2009521494A5 - - Google Patents

Download PDF

Info

Publication number
JP2009521494A5
JP2009521494A5 JP2008547727A JP2008547727A JP2009521494A5 JP 2009521494 A5 JP2009521494 A5 JP 2009521494A5 JP 2008547727 A JP2008547727 A JP 2008547727A JP 2008547727 A JP2008547727 A JP 2008547727A JP 2009521494 A5 JP2009521494 A5 JP 2009521494A5
Authority
JP
Japan
Prior art keywords
composition
alkyl
independently
membered ring
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008547727A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009521494A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2006/062307 external-priority patent/WO2007076360A1/en
Publication of JP2009521494A publication Critical patent/JP2009521494A/ja
Publication of JP2009521494A5 publication Critical patent/JP2009521494A5/ja
Pending legal-status Critical Current

Links

JP2008547727A 2005-12-22 2006-12-19 rhoキナーゼ媒介性疾患および状態を治療するための(インダゾール−5−イル)−ピラジンおよび(1,3−ジヒドロインドール−2−オン)−ピラジン Pending JP2009521494A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US75313605P 2005-12-22 2005-12-22
PCT/US2006/062307 WO2007076360A1 (en) 2005-12-22 2006-12-19 (indazol-5-yl)-pyrazines and (1,3-dihydro-indol-2-one)- pyrazines for treating rho kinase-mediated diseases and conditions

Publications (2)

Publication Number Publication Date
JP2009521494A JP2009521494A (ja) 2009-06-04
JP2009521494A5 true JP2009521494A5 (https=) 2011-02-03

Family

ID=37963712

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008547727A Pending JP2009521494A (ja) 2005-12-22 2006-12-19 rhoキナーゼ媒介性疾患および状態を治療するための(インダゾール−5−イル)−ピラジンおよび(1,3−ジヒドロインドール−2−オン)−ピラジン

Country Status (14)

Country Link
US (1) US7655662B2 (https=)
EP (1) EP1962853A1 (https=)
JP (1) JP2009521494A (https=)
KR (1) KR20080077652A (https=)
CN (1) CN101340912A (https=)
AR (1) AR058618A1 (https=)
BR (1) BRPI0620463A2 (https=)
CA (1) CA2629342A1 (https=)
MX (1) MX2008008328A (https=)
RU (1) RU2008130111A (https=)
TW (1) TW200733964A (https=)
UY (1) UY30058A1 (https=)
WO (1) WO2007076360A1 (https=)
ZA (1) ZA200804497B (https=)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007008942A2 (en) * 2005-07-11 2007-01-18 Aerie Pharmaceuticals, Inc. Phenylamino-acetic acid [1-(pyridin-4-yl)-methylidene]-hydrazide derivatives and related compounds as modulators of g protein-coupled receptor kinases for the treatment of eye diseases
WO2007008926A1 (en) * 2005-07-11 2007-01-18 Aerie Pharmaceuticals, Inc. Isoquinoline compounds
WO2008036540A2 (en) 2006-09-20 2008-03-27 Boehringer Ingelheim International Gmbh Rho kinase inhibitors
WO2008041118A2 (en) * 2006-10-04 2008-04-10 Pfizer Products Inc. Pyrido[4,3-d]pyrimidin-4(3h)-one derivatives as calcium receptor antagonists
US20100022517A1 (en) * 2006-12-18 2010-01-28 Richards Lori A Ophthalmic formulation of rho kinase inhibitor compound
US8455513B2 (en) 2007-01-10 2013-06-04 Aerie Pharmaceuticals, Inc. 6-aminoisoquinoline compounds
US8455514B2 (en) 2008-01-17 2013-06-04 Aerie Pharmaceuticals, Inc. 6-and 7-amino isoquinoline compounds and methods for making and using the same
WO2009155209A1 (en) * 2008-06-18 2009-12-23 Inspire Pharmaceuticals, Inc. Ophthalmic formulation of rho kinase inhibitor compound
US8450344B2 (en) 2008-07-25 2013-05-28 Aerie Pharmaceuticals, Inc. Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds
KR20170015566A (ko) 2008-11-10 2017-02-08 버텍스 파마슈티칼스 인코포레이티드 Atr 키나제의 억제제로서 유용한 화합물
ES2663222T3 (es) 2008-12-19 2018-04-11 Vertex Pharmaceuticals Incorporated Derivados de pirazina útiles como inhibidores de la quinasa ATR
EP3053913B1 (en) 2009-05-01 2018-03-07 Aerie Pharmaceuticals, Inc. Dual mechanism inhibitors for the treatment of disease
CN102822170B (zh) 2009-12-21 2014-12-10 阵列生物制药公司 作为cFMS抑制剂的取代的N-(1H-吲唑-4-基)咪唑并[1,2-a]吡啶-3-羧酰胺化合物
JP5856151B2 (ja) 2010-05-12 2016-02-09 バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated Atrキナーゼ阻害剤として有用な2−アミノピリジン誘導体
US9630956B2 (en) 2010-05-12 2017-04-25 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
JP2013526540A (ja) 2010-05-12 2013-06-24 バーテックス ファーマシューティカルズ インコーポレイテッド Atrキナーゼ阻害剤として有用な化合物
JP2013529200A (ja) 2010-05-12 2013-07-18 バーテックス ファーマシューティカルズ インコーポレイテッド Atrキナーゼ阻害剤として有用な化合物
US8969356B2 (en) 2010-05-12 2015-03-03 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
JP2013526539A (ja) 2010-05-12 2013-06-24 バーテックス ファーマシューティカルズ インコーポレイテッド Atrキナーゼ阻害剤として有用なピラジン
CA2803802A1 (en) 2010-06-23 2011-12-29 Vertex Pharmaceuticals Incorporated Pyrrolo- pyrazine derivatives useful as inhibitors of atr kinase
JP2014510151A (ja) 2011-04-05 2014-04-24 バーテックス ファーマシューティカルズ インコーポレイテッド Atrキナーゼ(trakinase)阻害剤として有用なアミノピラジン化合物
WO2012178125A1 (en) 2011-06-22 2012-12-27 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
EP2723745A1 (en) 2011-06-22 2014-04-30 Vertex Pharmaceuticals Inc. Compounds useful as inhibitors of atr kinase
WO2012178124A1 (en) 2011-06-22 2012-12-27 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
SG10201606774UA (en) 2011-09-30 2016-10-28 Vertex Pharma Processes for making compounds useful as inhibitors of atr kinase
KR20140084112A (ko) 2011-09-30 2014-07-04 버텍스 파마슈티칼스 인코포레이티드 Atr 키나제의 억제제로서 유용한 화합물
WO2013049859A1 (en) 2011-09-30 2013-04-04 Vertex Pharmaceuticals Incorporated Treating pancreatic cancer and non-small cell lung cancer with atr inhibitors
WO2013049719A1 (en) 2011-09-30 2013-04-04 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
US8853217B2 (en) 2011-09-30 2014-10-07 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
US8841337B2 (en) 2011-11-09 2014-09-23 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
US8841450B2 (en) 2011-11-09 2014-09-23 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
WO2013071094A1 (en) 2011-11-09 2013-05-16 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
WO2013071088A1 (en) 2011-11-09 2013-05-16 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
WO2013071085A1 (en) 2011-11-09 2013-05-16 Vertex Pharmaceuticals Incorporated Pyrazine compounds useful as inhibitors of atr kinase
CA2869309C (en) 2012-04-05 2021-02-09 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase and combination therapies thereof
US8999632B2 (en) 2012-10-04 2015-04-07 Vertex Pharmaceuticals Incorporated Method for measuring ATR inhibition mediated increases in DNA damage
US8912198B2 (en) 2012-10-16 2014-12-16 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
SI2941432T1 (en) 2012-12-07 2018-07-31 Vertex Pharmaceuticals Incorporated 2-AMINO-6-FLUORO-N- (5-FLUORO-4- (4- (4- (OXETHAN-3-YL) PIPERAZIN-1-CARBONYL) PIPERIDIN-1-YLIPRIDIN-3-YL) 1,5 ALFA) PYRIMIDINE-3-CARBOXAMIDE AS ATR KINAZE INHIBITOR
JP2016512815A (ja) 2013-03-15 2016-05-09 バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated Atrキナーゼの阻害剤として有用な縮合ピラゾロピリミジン誘導体
DK3811943T3 (da) 2013-03-15 2023-04-03 Aerie Pharmaceuticals Inc Forbindelse til anvendelse til behandling af øjenlidelser
US9328200B2 (en) * 2013-07-17 2016-05-03 Ultrasci Discovery Llp Branched polymeric quaternary ammonium compounds and their uses
DK3077397T3 (da) 2013-12-06 2019-12-16 Vertex Pharma 2-amino-6-fluor-n-[5-fluor-pyridin-3-yl]pyrazolo[1,5-a]pyrimidin-3-carboxamidforbindelse anvendelig som atr-kinase-inhibitor, dens fremstilling, forskellige faste former og radiomarkerede derivater deraf
PL3152212T3 (pl) 2014-06-05 2020-06-15 Vertex Pharmaceuticals Inc. Radioznakowane pochodne związku 2-amino-6-fluoro-n-[5-fluoro-piridyn-3-ylo]-pirazolo[1,5-a]pirymidino-3-karboksamidu przydatne jako inhibitor kinazy atr, wytwarzanie tego związku i jego różnych postaci stałych
LT3157566T (lt) 2014-06-17 2019-08-12 Vertex Pharmaceuticals Incorporated Vėžio gydymo būdas, panaudojant chk1 ir atr inhibitorių derinį
HK1258570A1 (zh) 2015-09-30 2019-11-15 Vertex Pharmaceuticals Inc. 使用dna损伤剂及atr抑制剂的组合治疗癌症的方法
US10550087B2 (en) 2015-11-17 2020-02-04 Aerie Pharmaceuticals, Inc. Process for the preparation of kinase inhibitors and intermediates thereof
US9643927B1 (en) 2015-11-17 2017-05-09 Aerie Pharmaceuticals, Inc. Process for the preparation of kinase inhibitors and intermediates thereof
KR102568079B1 (ko) 2016-08-31 2023-08-17 에어리 파마슈티컬즈, 인코포레이티드 안과용 조성물
KR20190135027A (ko) 2017-03-31 2019-12-05 에어리 파마슈티컬즈, 인코포레이티드 아릴 시클로프로필-아미노-이소퀴놀리닐 아미드 화합물
GEP20237548B (en) 2018-07-05 2023-10-10 Incyte Corp Fused pyrazine derivatives as a2a /a2b inhibitors
AU2019337703B2 (en) 2018-09-14 2023-02-02 Aerie Pharmaceuticals, Inc. Aryl cyclopropyl-amino-isoquinolinyl amide compounds
TWI829857B (zh) 2019-01-29 2024-01-21 美商英塞特公司 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
US12064376B2 (en) * 2020-06-03 2024-08-20 Glaukos Corporation Rho kinase inhibitor releasing implants and related methods of use

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0492903A1 (en) * 1990-12-21 1992-07-01 MERCK SHARP & DOHME LTD. Substituted pyrazines, pyrimidines and pyridazines for use in the treatment of glaucoma
PT868186E (pt) 1995-12-21 2005-05-31 Alcon Lab Inc Utilizacao de certos compostos de isoquinolinossulfonilo para tratamento de glaucoma e isquemia ocular
US6586425B2 (en) 1996-02-21 2003-07-01 Wisconsin Alumni Research Foundation Cytoskeletal active agents for glaucoma therapy
US5798380A (en) 1996-02-21 1998-08-25 Wisconsin Alumni Research Foundation Cytoskeletal active agents for glaucoma therapy
NZ513800A (en) 1996-08-12 2001-09-28 Welfide Corp Treatment of diseases using Rho kinase inhibitors
CA2214841A1 (en) 1997-10-31 1999-04-30 Lisa Mckerracher Rho antagonists and their use to block inhibition of neurite outgrowth
AU5198199A (en) 1998-08-17 2000-03-06 Senju Pharmaceutical Co., Ltd. Preventives/remedies for glaucoma
EP1177796B1 (en) 1999-04-27 2011-04-27 Mitsubishi Tanabe Pharma Corporation Medicament for prevention or therapeutic treatment of liver disease
JP3430254B2 (ja) 2000-03-13 2003-07-28 独立行政法人産業技術総合研究所 β−ジケトナートを有する金属錯体及びその製法、光電変換素子並びに、光化学電池
JP4776136B2 (ja) 2000-03-16 2011-09-21 田辺三菱製薬株式会社 アミド化合物およびその用途
AU2001236006A1 (en) 2000-03-31 2001-10-15 Mitsubishi Pharma Corporation Preventives/remedies for kidney diseases
JPWO2002100833A1 (ja) 2001-06-12 2004-09-24 住友製薬株式会社 Rhoキナーゼ阻害剤
US20030187026A1 (en) 2001-12-13 2003-10-02 Qun Li Kinase inhibitors
DE60320933D1 (de) 2002-01-10 2008-06-26 Bayer Healthcare Ag Rho-kinase inhibitoren
MXPA04007196A (es) 2002-01-23 2005-06-08 Bayer Pharmaceuticals Corp Inhibidores de rho-quinasa.
GB0206860D0 (en) * 2002-03-22 2002-05-01 Glaxo Group Ltd Compounds
US7015227B2 (en) 2002-06-21 2006-03-21 Cgi Pharmaceuticals, Inc. Certain amino-substituted monocycles as kinase modulators
AU2003281623B8 (en) 2002-07-22 2009-06-11 Asahi Kasei Pharma Corporation 5-substituted isoquinoline derivative
EP1550660A1 (en) 2002-09-12 2005-07-06 Kirin Beer Kabushiki Kaisha Isoquinoline derivatives having kinasae inhibitory activity and drugs containing the same
WO2004084824A2 (en) 2003-03-24 2004-10-07 Merck & Co., Inc. Biaryl substituted 6-membered heterocyles as sodium channel blockers
GB2400101A (en) 2003-03-28 2004-10-06 Biofocus Discovery Ltd Compounds capable of binding to the active site of protein kinases
CA2530389A1 (en) * 2003-07-02 2005-01-13 Biofocus Discovery Limited Pyrazine and pyridine derivatives as rho kinase inhibitors
AU2004278382B2 (en) 2003-09-30 2008-09-18 Amgen Inc. Vanilloid receptor ligands and their use in treatments
WO2006071548A2 (en) * 2004-12-27 2006-07-06 Alcon, Inc. Aminopyrazine analogs for treating glaucoma and other rho kinase-mediated diseases

Similar Documents

Publication Publication Date Title
JP2009521494A5 (https=)
ES2601820T5 (es) Moduladores de propiedades terapéutica de las farmacocinéticas
US11512060B2 (en) 1,2,4-oxadiazole derivatives as immunomodulators
RU2008130111A (ru) (индазол-5-ил)пиразины и (1,3-дигидроиндол-2-он)пиразины для лечения опосредованнызх rно-киназой заболеваний и состояний
CA2590261A1 (en) Aminopyrazine analogs for treating glaucoma and other rho kinase-mediated diseases and conditions
ES3026665T3 (en) Modulators of pharmacokinetic properties of therapeutics
JP2022081661A5 (https=)
ES2399314T3 (es) Gamma lactamas sustituidas como agentes terapeúticos
JP5918848B2 (ja) ベンゾチアゾール化合物およびその薬学的使用
TWI500616B (zh) 新穎之雙環吡啶酮
JP7044392B2 (ja) マラリアの治療のための化合物及び方法
RU2005132930A (ru) Аналоги простагландина в качестве антагонистов ep4 рецепторов
JP2001526218A5 (https=)
CN107105660A (zh) 使用替唑尼特、其类似物或盐的前药的治疗组合物和治疗方法
GEP20094723B (en) Tetraazabenzo [e] azulene derivatives and analogs thereof
TW200305425A (en) 8-Azaprostaglandin derivatives and medicament containing same as active ingredient
JP2004526788A5 (https=)
JP2006507220A5 (https=)
EA037327B1 (ru) Соединения и композиции для лечения глазных расстройств
CA2488001A1 (en) 1,5-distributed pyrrolid-2-one derivatives for use as ep4 receptor agonists in the treatment of eye diseases such as glaucoma
RU2011108485A (ru) Новые (поли)аминоалкиламиноалкиламидные, алкилмочевинные или алкилсульфонамидные производные эпиподофиллотоксина, способ их получения и их применение в терапии в качестве противораковых средств
CA2589744A1 (en) Pyrrolinidium derivatives as m3 muscarinic receptors
JP2013522321A (ja) Hivを治療するためのccr5モジュレーター
JP2004538278A5 (https=)
CN1525969A (zh) 用于治疗青光眼和近视的苯并[g]喹啉衍生物